OTCMKTS:BAYRY

Bayer Aktiengesellschaft Q2 2025 Earnings Report

Bayer Aktiengesellschaft logo
$13.16 +1.91 (+16.98%)
As of 03:59 PM Eastern

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.35
Consensus EPS
$0.25
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$12.42 billion
Expected Revenue
$10.79 billion
Beat/Miss
Beat by +$1.63 billion
YoY Revenue Growth
N/A

Bayer Aktiengesellschaft Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, August 4, 2026, based on past reporting schedules.

Conference Call Resources

Bayer Aktiengesellschaft Earnings Headlines

PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.tc pixel
Bayer To Cut 12,000 Jobs Following Monsanto Purchase
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates. Its Consumer Health segment produces and markets nonprescription medicines and self-care products intended for a broad global audience. The Crop Science division supplies seeds, crop protection products and digital farming tools to farmers and agribusinesses, integrating agronomic services with chemical and seed portfolios to address productivity and sustainability challenges.

Key historical milestones include the company’s founding in the 19th century and substantial expansion through acquisitions, most notably the 2018 purchase of Monsanto, which significantly expanded Bayer’s seed and crop protection footprint. That acquisition also brought high-profile legal and regulatory matters related to glyphosate-based products, which have been a notable element of the company’s recent corporate history. Bayer conducts operations across Europe, the Americas, Asia-Pacific and other regions, with global manufacturing, research centers and commercial organizations.

Bayer is governed by a board of management and a supervisory board and invests heavily in research and development to sustain long-term product pipelines in health and agriculture. The company’s activities emphasize innovation, regulatory compliance and global market presence while navigating complex legal, environmental and commercial landscapes typical for a multinational life sciences firm.

View Bayer Aktiengesellschaft Profile